TABLE 2.
Disease and Treatment-Related Characteristics of the Patients
| C+ (n = 28) | C− (n = 20) | p | |
|---|---|---|---|
| KPSa | 80 (70–100) | 90 (70–100) | 0.08 |
| Histologyb | |||
| SCLC | 28 (100) | ||
| NSCLC | |||
| Adenocarcinoma | 11 (55) | ||
| Squamous-cell carcinoma | 8 (40) | ||
| Nonclassified | 1 (5) | ||
| Tumor stageb | |||
| Limited disease | 22 (79) | ||
| Extensive disease | 6 (21) | ||
| IIB | 2 (10) | ||
| IIIA | 11 (55) | ||
| IIIB | 7(35) | ||
| Chemo typeb | |||
| CDDP-based | 21 (75) | ||
| CBDCA-based | 7 (25) | ||
| Number of chemo cyclesa | 4 (3–6) | ||
| Thoracic radiationb | 25 (89) | ||
a
median (range).
b
n (%).
C+, chemotherapy-treated small-cell lung cancer group; C−, nonchemotherapy treated non–small-cell lung cancer group; KPS, Karnosfky performance scale; SCLC, small-cell lung cancer; NSCLC, non–small-cell lung cancer; CDDP, cisplatin; CBDCA, carboplatin.